News >

Frontline Atezolizumab Regimen Improves PFS in NSCLC

Silas Inman @silasinman
Published: Thursday, Dec 07, 2017

Dr. Martin Reck

Martin Reck, MD, PhD
Treatment with the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer (NSCLC), according to findings from the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress.

<.0001). The ORR in this group was 69% with atezolizumab compared with 54% without the PD-L1 inhibitor. The 12-month PFS rate was 18% with bevacizumab/chemotherapy and 46% with the addition of atezolizumab.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x